Actively Recruiting
Evaluation of Safety, Tolerability, and Protective Effect of PfSPZ-LARC2 Vaccine Against Malaria Infection in Healthy Adults
Led by Sanaria Inc. · Updated on 2026-11-03
42
Participants Needed
1
Research Sites
17 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety, tolerability, and protective effect of the Plasmodium falciparum sporozoite late-arresting replication-competent malaria vaccine PfSPZ-LARC2 Vaccine in healthy adults who have not previously been exposed to malaria. This Phase 1 randomized, double-blind, placebo-controlled study is conducted in Germany to assess how well the vaccine prevents controlled human malaria infection CHMI. Participants receive the vaccine or a saline placebo through direct venous inoculation in two parts. Part A involves a three-dose regimen given on Days 1, 6, and 29, followed by CHMI three weeks after the final dose to test protective efficacy. If necessary, Part B will increase the vaccine dose and adjust the schedule to improve protection, with doses on Days 1, 29, and 57 and CHMI conducted 12 weeks after the last dose. Monitoring includes blood tests to detect malaria parasites, safety assessments, and clinical evaluations throughout. During the study, participants undergo regular blood sampling and clinical checks to monitor for malaria infection and adverse events. Detailed safety monitoring occurs after each vaccination and during the CHMI period. Participants receive antimalarial treatment if infection is detected and have follow-up visits including laboratory testing, physical exams, and immune response sampling to confirm safety and vaccine effects. The study lasts several months, with close observation before, during, and after vaccination and challenge phases.
CONDITIONS
Brief Title
Safety, Tolerability and Efficacy of PfSPZ-LARC2 Vaccine Against CHMI in Malaria-Naïve Adults
Research Team
P
Peter Kremsner, MD
A
Andrea Kreidenweiss, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here